Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer

被引：0
|
作者：
M Gijsen
P King
T Perera
P Parker
B Larijani
A Harris
A Kong
机构：
[1] University of Oxford,Cancer Research UK
[2] Johnson & Johnson Pharmaceutical Research & Development,undefined
[3] London Research Institute,undefined
来源：
Breast Cancer Research | / 12卷
关键词：
Breast Cancer; Trastuzumab; Feedback Loop; Xenograft Model; Fluorescence Resonance Energy Transfer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
    Gijsen, M.
    King, P.
    Perera, T.
    Parker, P.
    Larijani, B.
    Harris, A.
    Kong, A.
    BREAST CANCER RESEARCH, 2010, 12 : S1 - S1
  • [2] Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
    Luque-Cabal, Maria
    Garcia-Teijido, Paula
    Fernandez-Perez, Yolanda
    Sanchez-Lorenzo, Luisa
    Palacio-Vazquez, Isabel
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 21 - 30
  • [3] HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
    Gajria, Devika
    Chandarlapaty, Sarat
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 263 - 275
  • [4] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Park, Juin
    Kang, Sun Kyoung
    Kwon, Woo Sun
    Jeong, Inhye
    Kim, Tae Soo
    Yu, Seo Young
    Cho, Sang Woo
    Chung, Hyun Cheol
    Rha, Sun Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
    Nami, Babak
    Wang, Zhixiang
    CANCERS, 2017, 9 (05):
  • [6] Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells
    Yoshioka, Takahiro
    Shien, Kazuhiko
    Takeda, Tatsuaki
    Takahashi, Yuta
    Kurihara, Eisuke
    Ogoshi, Yusuke
    Namba, Kei
    Torigoe, Hidejiro
    Sato, Hiroki
    Tomida, Shuta
    Yamamoto, Hiromasa
    Soh, Junichi
    Fujiwara, Toshiyoshi
    Toyooka, Shinichi
    CANCER SCIENCE, 2019, 110 (08) : 2549 - 2557
  • [7] Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
    Nafi, Siti Norasikin Mohd
    Generali, Daniele
    Kramer-Marek, Gabriela
    Gijsen, Merel
    Strina, Carla
    Cappelletti, Mariarosa
    Andreis, Daniele
    Haider, Syed
    Li, Ji-Liang
    Bridges, Esther
    Capala, Jacek
    Ioannis, Roxanis
    Harris, Adrian L.
    Kong, Anthony
    ONCOTARGET, 2014, 5 (15) : 5934 - 5949
  • [8] Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
    Canonici, Alexandra
    Gijsen, Merel
    Mullooly, Maeve
    Bennett, Ruth
    Bouguern, Noujoude
    Pedersen, Kasper
    O'Brien, Neil A.
    Roxanis, Ioannis
    Li, Ji-Liang
    Bridge, Esther
    Finn, Richard
    Slamon, Dennis
    McGowan, Patricia
    Duffy, Michael J.
    O'Donovan, Norma
    Crown, John
    Kong, Anthony
    ONCOTARGET, 2013, 4 (10) : 1592 - 1605
  • [9] ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
    Feldinger, Katharina
    Generali, Daniele
    Kramer-Marek, Gabriela
    Gijsen, Merel
    Ng, Tzi Bun
    Wong, Jack Ho
    Strina, Carla
    Cappelletti, Mariarosa
    Andreis, Daniele
    Li, Ji-Liang
    Bridges, Esther
    Turley, Helen
    Leek, Russell
    Roxanis, Ioannis
    Capala, Jacek
    Murphy, Gillian
    Harris, Adrian L.
    Kong, Anthony
    ONCOTARGET, 2014, 5 (16) : 6633 - 6646
  • [10] Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
    Li, Xin
    Xu, Yuxiu
    Ding, Yun
    Li, Changfei
    Zhao, Hong
    Wang, Jiandong
    Meng, Songdong
    MOLECULAR CANCER, 2018, 17
12345